Al Hikma announced the exclusive multinational pharmaceutical and fast growing group of companies with its exclusive licensing, supply and distribution agreement with Milenta Therapeutics, regarding intravenous and oral formulations of its product (Baxdeladelafloxacin) throughout the eastern region. Middle and North Africa.
In a statement, we obtained a copy of it, that the company granted you the right of pre-emption for all other products in the Melinta portfolio, and its products are under implementation in the region.
Baxdela is a new antibiotic used to treat adult patients with acute bacterial skin infections or those that affect the skin structure (ABSSSI), and contains fluoroquinolone that fights positive pathogens Gram and Gram-negative, including methicillin-resistant Staphylococcus aureus (MRSA) infection. This product obtained FDA approval in 2017.
= RTL "style =" text-align: justify; "> In the field of providing antibiotics in the MENA region, Wisdom has emerged as a leader providing a wide range of products to doctors and pharmacists, including AMR continues to pose therapeutic challenges for doctors, and the launch of this new and innovative product in the region will provide them with new methods to combat this growing threat.
The company announced the beginning of last year in cooperation with Eisai Europe Limited, the world leader in drug research and development and committed to discovering and developing innovative neurological treatments, the availability of Perampanel treatment In the Kingdom of Saudi Arabia, to provide adjunctive treatment for partial epileptic seizures with or without their transformation into secondary general epileptic seizures for patients over 12 years of age.
